Oct 13 (Reuters) - Regenerative products manufacturer Direct Biologics plans to list in the United States by merging with blank-check firm Good Works II Acquisition Corp in a deal valued at $1.03 billion, including debt. (Reporting by Mehnaz Yasmin in Bengaluru; Editing by Devika Syamnath)
Good Works II Acquisition Corp.
Equities
GWII
US38216G1040
Investment Holding Companies
1st Jan change | Capi. | |
---|---|---|
+198.00% | 7.13B | |
+2.19% | 982M | |
+41.91% | 872M | |
+25.43% | 820M | |
+1.77% | 664M | |
+6.82% | 648M | |
-.--% | 600M | |
+3.61% | 503M | |
-.--% | 500M |